Date: 28th September 2018
Venue: General Hospital Vienna, Austria
On Friday 28th of September the annual meeting 2018 of the Austrian Competence Network on Mastocytosis (AUCNM) was held at the General Hospital Vienna.
The AUCNM is a partner and important element of the European Competence Network on Mastocytosis (ECNM), where a group of clinicians and scientists in Europe establish a network of centers and experts working in the field of mastocytosis.
Mastocytosis is a rare disorder which displays abnormal growth and accumulation of tissue mast cells in the skin or internal organs.
The aim of the annual meetings is to strengthen the network and to establish local guidelines for diagnosis and therapy of mastocytosis.
Education Workshop on Mastocytosis of ECNM and AUCNM
Date: 27th September 2018
Venue: Hotel Melia, DC Tower Vienna, Vienna, Austria
On September 27th 2018 the Education Workshop Mastocytosis of the European Competence Network on Mastocytosis (ECNM) and Austrian Competence Network on Mastocytosis (AUCNM) was held to discuss about the latest status of diagnosis and therapy of mastocytosis.
The ECNM is a cooperative initiative of a group of clinicians and scientists in Europe who regularly come together to improve diagnostic and therapeutic options in patients with mastocytosis.
The AUCNM, as an austrian competence-network, functions as important element and partner of the ECNM.
Mastocytosis is a disease with abnormal growing mast cells in the skin, in internal organs or both skin and internal organs. As a result, mastocytosis is a disease with extensive accumulated mast cells (too many mast cells) in a patient´s body. Both children and adults can develop mastocytosis. It is classified in cutaneous mastocytosis (CM) or systemic mastocytosis (SM). In 2001, the WHO has introduced mastocytosis as a clonal hematopoietic disease in their classification of blood cell disorders.
At the workshop in September the status of bone marrow patterns and molecular markers in mastocytosis was discussed. Furthermore, the participants focused on the treatment of patients with indolent and advanced forms of mastocytosis.
Standards and Standardization in Chronic Myelomonocytic Leukemia
Date: 24th to 26th August 2018
Venue: Hilton Danube Waterfront Hotel Vienna, Austria
On August 24th-26th 2018 the meeting “Standards and Standardization in Chronic Myelomonocytic Leukemia” was held in Vienna as a result of the EU-US multicenter cooperative initiative to standardize parameters of disease and diagnostics for practice and clinical trials in patients with chronic myelomonocytic leukemia (CMML).
The first day of the conference was open to visitors and all interested colleagues who had the opportunity to hear state-of-the-art lectures from world leading experts in CMML on numerous important topics ranging from morphology and histology, cytogenetics and molecular features, as well as application of flow cytometry, prognostic scoring and current recommendations and novel treatment approaches for patients with CMML. The second and third day marked the closed part of the working conference where scientific talks from the faculty were followed by intensive discussions aimed at reaching a consensus regarding diagnostic, prognostic and treatment procedures in CMML patients. The conclusions reached at the end of the meeting were summarized in the manuscript “Proposed diagnostic criteria for classical CMML, CMML variants and pre-CMML conditions” published in journal Haematologica in 2019 (doi: 10.3324/haematol.2019.222059).
10th Jubilee Meeting of the Ludwig Boltzmann Cluster Oncology
Date: 4th April 2018
Venue: Medical University of Vienna, Van Swieten Saal, 1090 Vienna, Austria
The Ludwig Boltzmann Cluster Oncology has celebrated it’s 10th year with a Jubilee Meeting on April 4th, 2018.
The highlights of the day were an overview of 50 years leukemia research within the Ludwig Boltzmann Gesellschaft presented by Michael Pfeilstöcker (Hanusch Hospital) and the keynote lecture by Tsvee Lapidot (Rehovot, Israel) about deciphering stem cell‐niche interactions in hematopoiesis. During the meeting, scientists from the LBC ONC and from cooperating institutions presented their research projects within the LBC ONC.
The research within the LBC ONC focusses on i) identification and characterization of leukemic stem cells (LSC) in myeloid and lymphoid neoplasms, ii) identification of clinically relevant therapeutic targets in LSC, iii) examining the effects of various targeted drugs and drug combinations on growth and survival of LSC.
A further aim of the LBC ONC is to provide a multidisciplinary platform for interactive, cooperative research on LSC in Vienna and Austria and to promote collaborations with national and international partners and networks working in the field of LSC.
In addition, the LBC ONC aims to educate young scientists interested in LSC research, to promote junior group leaders and to motivate clinical colleagues to translate LSC concepts into clinics.
The ultimate goal of the LBC ONC is to enable development of novel treatment concepts based on LSC eradication.
To reach this goal, the LBC ONC has established a series of collaboration platforms and organized a series of international meetings and conferences on LSC in the past 10 years.